GLP-1 medications should be seen as part of a comprehensive strategy not a standalone fix Disclaimers and Disclosures The information provided in this article is for general informational and educational purposes only and is not intended as, nor should it be construed or substituted as, medical advice, diagnosis, or treatment
162,163 Retatrutide (LY-3437943), a novel triple agonist developed by Eli Lilly that targets GLP-1R, GIPR and GCGR, has shown potential in preliminary clinical data for providing excellent blood sugar control and significant weight reduction
For weight management , non-pharmacological approaches are strongly recommended: Dietary modification : Working with a registered dietitian to develop a balanced eating plan that maintains adequate nutrition for milk production Physical activity : Gradual return to exercise as appropriate postpartum Behavioural support : Structured weight management programmes that address lifestyle factors Breastfeeding itself supports metabolic health and gradual postpartum weight loss
Retatrutide is a synthetic triple-agonist peptide that activates GLP-1, GIP, and glucagon receptors simultaneously
